SCPH SCPharmaceuticals Inc

scPharmaceuticals to Present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference

scPharmaceuticals to Present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference

BURLINGTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference on Thursday, December 3 at 11:20am EST.

A live webcast of the presentation can be accessed under “News & Events” in the Investor Relations section of the Company’s website, .

About scPharmaceuticals

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit

Katherine Taudvin

scPharmaceuticals Inc., 781-301-6706

Investors:

Hans Vitzthum

LifeSci Advisors, 617-430-7578

Media:

Kate Coyle

ICR Inc., 203-682-8210



EN
19/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCPharmaceuticals Inc

 PRESS RELEASE

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Reve...

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPharmaceuticals is expected to diversify and accelerate MannKind’s double-digit revenue growth, driven by FUROSCIX® (furosemide injection), an innovative therapy for edema due to chronic heart failure and chronic kidney disease. The transaction will strengthen MannKind’s co...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch